Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu • (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.
A mouse model and previous studies suggest that genetic intervention in SHANK3-related ASD may be most effective earlier in development.
Results show that retinitis pigmentosa 59 may not be a congenital disorder of glycosylation, as was long assumed.
Everyone was fast this spring: the businesses that contributed to the fund, the scientists and physicians who crafted research proposals, and the senior School of Medicine researchers who chose which proposals got money.
The complement system is part of the body’s immune system to fight pathogens and remove cell debris. Its role in two autoimmune diseases and a mental disorder is a surprise.
Dual antiplatelet therapy after percutaneous coronary intervention uses aspirin and one other drug, among several choices. But which drug is best to use?
This discovery may have clinical importance in management of heart failure.
A microbiome “fingerprint” method allows tracking of mothers’ microbial strains inherited by infants.
The research is led by an Oregon cancer research institute, in collaboration with two biotech companies and the National Institutes of Health.
UAB Department of Cell, Developmental and Integrative Biology ranks fourth in nation for NIH funding
The ranking measured 79 anatomy/cell biology departments in U.S. medical schools.
The work centers around ReFRAME, a vast collection of drugs developed for other diseases that are already known to be safe for humans.